

Clinical distribution and antibiotic resistance of *Pseudomonas* species*

ERGİN Ç.¹, MUTLU G.²

Department of Clinical Microbiology¹, School of Medicine, Süleyman Demirel University, Isparta

Department of Clinical Microbiology², School of Medicine, Akdeniz University, Antalya

Objective The aim of this study was to determine the isolation properties of *Pseudomonas aeruginosa* and other species, distribution rates in clinics and resistance to antibiotics in Akdeniz University Hospital.

Method *Pseudomonas* bacteria were isolated and identified by conventional methods. The antibiotic resistance rates were detected by minimal inhibitory concentration (MIC). The clinical and specimen distribution properties of *Pseudomonas* were evaluated based on their resistance.

Results *Pseudomonas* bacteria were the fourth common in

		CRO	CTX	CAZ	OFX	CIP
Tracheal asp.	SW-ICU	p<0.001	p<0.001	p>0.05	p<0.001	p<0.001
Wound pus	SW-ICU	p<0.001	p<0.001	p<0.001	p<0.001	p<0.001
Sputum	SW-nonICU	p<0.001	p<0.001	p<0.05	p>0.05	p>0.05
Wound pus	SW-nonICU	p<0.001	p<0.001	p>0.05	p<0.001	p<0.001

No resistance to imipenem was observed.

Conclusion These data show that it would be useful to apply more effective antibiotic control programmes in surgery wards.

all isolates. Tracheal aspirates, sputum and wound pus were important sources for *P.aeruginosa* isolation in intensive and nonintensive care units of surgery wards (SW-ICU, SW-nonICU) (p<0.05). On the basis of MIC₉₀ criteria, the resistance ratios of the isolates to ceftriaxone (CRO), cefotaxime (CTX), ceftazidime (CAZ), imipenem (IP), ofloxacin (OFX), ciprofloxacin (CIP) were 8.4%, 15.0%, 13.3%, 0.0%, 11.6% and 8.3% respectively. The table illustrates the statistical properties of the resistance of isolates which show significant relations between clinics and specimens.

Key words *Pseudomonas* species, resistance

Introduction

Pseudomonas aeruginosa remains an important cause of hospital-acquired infections particularly among immunosuppressed patients (and those carrying prosthetic devices) in intensive care units (ICU). The diversity of clinics and the regional variations in antibiotic protocols result in the different resistance profiles (1-3).

In this study, isolation, distribution and susceptibility properties of *P.aeruginosa* and other species were determined in Akdeniz University Hospital.

Material and Method

Akdeniz University Hospital has 400 beds and receives about 7500 admissions per year. On each floor, there are two or three clinics and each room contains six beds. There is an infection control committee in the university hospital. Only patients in internal wards-ICU are not moved, but those in all other wards may be moved between wards and floors.

Only 7438 samples were evaluated in the first six-month period of 1995. Giemsa and gram stained smears of sputum and tracheal aspirates were evaluated for quality scores. The Bact/Alert system

*Presented in 8th International Congress on Infectious Diseases, Boston, Massachusetts, USA, May 15-18, 1998

Accepted for publication: 12 June 1998

from immunosuppressive patients were evaluated according to prominent colonies and clinical correlations.

Identification

The isolates were identified by conventional methods. Strains were identified as *Pseudomonas* on the basis of colony morphology, gram stain, oxidase reaction, development of pyocyanin pigments and urease enzyme, nitrate reduction and production of gases, gelatin hydrolysis, uses of citrate and malonate as a carbon source, growing capability at 5°C and 42°C. Glucose, lactose, maltose, mannitol, sucrose and xylose were used to investigate the acide production in sugars.

Susceptibility tests

The susceptibility testing of *P.aeruginosa* was performed with standardized broth MIC tests according to NCCLS suggestions.

Statistical analysis

The SPSS for Windows Ver 6.0 was used for statistical analysis. Multiple-line khi-square analysis was done (Table VIII).

Results

The rate of pathogenic bacteria was 32.72% in 7438 samples. The nonfermentative gram (-) bacilli were the fourth common bacteria in all isolates

(Table I). *Pseudomonas* sp were the most common bacteria out of all nonfermentative gram (-) rods (Table II). *P.aeruginosa* was the commonest bacteria out of all *Pseudomonas* species (Table III). *Pseudomonas* sp. were the most frequently isolated from ICU ($p<0.05$, Table IV). *Pseudomonas* sp. were the most frequently isolated from surgical wards ($p<0.05$, Table V). There is no difference in isolation rate between SW-ICU and SW-nonICU ($p>0.05$, Table VI). There was a higher isolation rate in IW-ICU than IW-nonICU ($p<0.05$, Table VII). Isolation rates of *Pseudomonas* sp from tracheal aspirate, sputum, pus and catheter samples were higher than the other samples.

Table I. Types of bacteria isolates from samples

Bacteria	Isolation		Rate in total (n=7438) %
	n	%	
Staphylococcus sp.	681	27.98	9.16
Streptococcus sp.	588	24.16	7.91
Enterobacteriaceae	586	24.08	7.88
Nonfermentative Gr(-) Bacilli	286	11.74	3.84
Yeasts	190	7.80	2.55
Gr(+) Bacilli	60	2.47	0.80
Others*	43	1.77	0.58
Total	2434	100.00	32.72

*:Neisseria sp, Haemophilus sp, Aeromonas sp

Table II. Distribution of nonfermentative gram (-) rods

Nonfermentative gram-negative rods	Isolation (n)	Distribution rate (%)
<i>Pseudomonas</i> sp.	192	67.13
<i>Acinetobacter</i> sp.	62	21.68
<i>Alcaligenes</i> sp.	8	2.80
<i>Xanthomonas maltophilia</i>	6	2.10
<i>Ochrobactrum anthropi</i>	5	1.75
<i>Oligella urethralis</i>	1	0.35
Unidentified	12	4.19
Total	286	100.00

Table III. Distribution of *Pseudomonas* by species

<i>Pseudomonas</i> sp.	Isolation (n)	Distribution rate (%)
<i>Pseudomonas aeruginosa</i>	176	91.67
<i>Pseudomonas cepacia</i>	10	5.21
<i>Pseudomonas putida</i>	2	1.04
<i>Pseudomonas stutzeri</i>	2	1.04
<i>Pseudomonas vesicularis</i>	1	0.52
<i>Pseudomonas mendocina</i>	1	0.52
Total	192	100.00

Table IV. *Pseudomonas* species isolated from ICU and non-ICU

	Total sample	<i>Pseudomonas</i> sp.	%
Intensive Care Units	1528	67	4.38

(ICU)	Total sample	<i>Pseudomonas</i> sp.	%
Non-Intensive Care units (nonICU)	5910	125	2.11

$p<0.05$

Table V. *Pseudomonas* species isolated from surgical wards and internal wards

	Total sample	<i>Pseudomonas</i> sp.	%
Surgery Wards (SW)	2397	112	4.67
Internal Wards (IW)	5041	80	1.58

$p<0.05$

Table VI. *Pseudomonas* species isolated from SW-ICU and SW-nonICU

	Total sample	<i>Pseudomonas</i> sp.	%
Surgery Wards-Intensive Care Unit (SW-ICU)	1023	51	4.98
Surgery Wards-Non Intensive Care Unit (SW-nonICU)	1374	61	4.43

$p>0.05$

Table VII. *Pseudomonas* species isolated from IW-ICU and IW-nonICU

	Total sample	<i>Pseudomonas</i> sp.	%
Internal Wards-Intensive Care Units (IW-ICU)	505	16	3.16
Internal Wards-Non Intensive Care Units (IW-nonICU)	4536	64	1.41

$p<0.05$

Table VIII. Distribution of isolation frequency by sample

Sample	Amount (N)	<i>Pseudomonas</i> sp. (n)	(%)	p
Tracheal aspiration	97	19	19.59	<0.05
Sputum	427	48	11.27	<0.05
Wound pus	842	63	7.48	<0.05
Catheter	53	2	3.77	<0.05
Urine	2331	46	1.97	>0.05
Blood	1210	7	0.58	>0.05
Throat*	1186	5	0.42	>0.05
Periton	321	1	0.31	>0.05
Stool*	635	1	0.16	>0.05
Others	336	0	0.00	>0.05
Total	7438	192	2.58	-

*: Preccence of immunosuppressive conditions

It was investigated whether or not there is any relationship between sample and unit on frequency of *Pseudomonas* sp isolates. The isolation rates of *Pseudomonas* were higher from sputum and pus in SW, tracheal aspirates and pus

in SW-ICU and tracheal aspirates in IW-ICU (Table IX).

Table IX. Distribution of *Pseudomonas* sp. in various units

		IW	SW	IW-nonICU	SW-nonICU
Tracheal Aspiration	Sample (n)			60	27
	<i>Pseudomonas</i> sp.	-	-	2	17
	%			3.33	62.96
	p			p>0.05	p<0.001
Sputum	Sample (n)	280	48	22	77
	<i>Pseudomonas</i> sp.	20	8	5	15
	%	7.14	16.66	22.72	19.48
	P	p>0.05	p<0.001	p>0.05	p>0.05
Wound pus	Sample (n)	111	642	39	50
	<i>Pseudomonas</i> sp.	13	27	6	17
	%	11.71	4.2	15.38	34
	p	p>0.05	p<0.001	p>0.05	p<0.05
Catheter	Sample (n)				28
	<i>Pseudomonas</i> sp.	-	-	-	2
	%				7.14
	p				p>0.05

Table X. MIC₉₀ values and resistance percentages of *P.aeruginosa*

Antibiotic	MIC ₉₀ (µg/ml)	Resistant rate(%)
Ceftriaxone (CRO)	32	8.4
Cefotaxime (CTX)	64	15.0
Ceftazidime (CAZ)	32	13.3
Imipenem (IP)	1	0.0
Ofloxacin (OFX)	16	11.6
Ciprofloxacin (CIP)	2	8.3

No resistance to imipenem was found. The highest resistance was to cefotaxime and ceftazidime (Table X).

Table XI shows cross-table statistical analysis of antibiotics and isolation sites which have significant p values in Table IX.

Table XI. Statistical properties of isolate resistance

		CRO	CTX	CAZ	IP	OFX	CIP
Tracheal aspiration (N=27; n=17)	SW-ICU	p<0.001	p<0.001	p>0.05	NT	p<0.001	p<0.001
Wound pus (N=50; n=17)	SW-ICU	p<0.001	p<0.001	p<0.001	NT	p<0.001	p<0.001
Sputum (N=48; n=8)	SW-nonICU	p<0.001	p<0.001	p<0.05	NT	p>0.05	p>0.05
Wound pus (N=642; n=27)	SW-nonICU	p<0.001	p<0.001	p>0.05	NT	p<0.001	p<0.001
Resistance rates (%)		8.4	15.0	13.3	0.0	11.6	8.3

NT: Not tested (resistance rate= 0.0)

N: Frequency of isolation site n: Frequency of isolated *P.aeruginosa*

Discussion

Pseudomonas aeruginosa is a major cause of nosocomial infection. Despite advances in sanitation facilities and the introduction of wide variety of antimicrobial agents with antipseudomonal activities, life-treating infections caused by *P.aeruginosa* continue to be hospital infections. The distribution of isolates is significantly effected by the type of hospital (general, teaching or specialized). Isolation due to nosocomial infection was 3-16% in multi-center studies. *P.aeruginosa* was the most common pathogen in nosocomial infections. It is the leading

cause of nosocomial respiratory tract infections (3-9). Our findings support this results (Table I-III, VIII).

Nonfermentative gram negative rods are environmental organisms. They are infrequently found as a part of the human microflora of healthy individuals. *P.aeruginosa* is more frequently isolated than other nonfermentative gram negative rods. It carries importance as a nosocomial pathogen; the isolation rate was 68.4% (10).

P.cepacia was the second common pathogen after *P.aeruginosa*. It was established in immunosuppressed patients with respiratory tract infections and it is a contaminant bacteria in pharmaceutical industries. Its

isolation rate was 3.1-4% (10-11). Our result (5.21%) was consistent with this percentage.

P.putida was the agent of catheter-related bacteremia, isolated from sputum, pus, joint and peritoneal fluid and urine related infections. The isolation rate was 1.1% in Suzuki's study (10). This was similar to ours (1.04%).

P.stutzeri is an unusual cause of human infection and it was reported as a pathogen in 1895. It was isolated from urine, blood, respiratory tract of intubated patients and wounds (11-12). In the report of Noble et al, the isolation rate of *P.stutzeri* was 2.0% (12). This percentage was higher than our result.

P.vesicularis may frequently colonize aqueous hospital environments. *P.vesicularis* bacteremia, genital and wound infections were reported (13-15). Our *P.vesicularis* bacteria were isolated from wound.

P.mendocina is an industrial bacteria used for alginate synthesis. It was reported as an agent of endocarditis (16). *P.mendocina* was isolated from peritoneal dialysate in our study.

Pseudomonas species other than *aeruginosa* are less virulent. Immunosuppression, contaminated disinfectant solutions and transfusion products and use of auxiliary medical equipment are predisposing factors leading to low virulent bacteria becoming an agent of infection. Intensive care patients create an environment for infection because of the debilitating effect of a prolonged hospitalisation and the application of medical equipment (airways, catheters etc) (2,3,17). Isolation rate of *Pseudomonas* sp. was significant for ICU in our study ($p < 0.05$, Table IV).

Surgical wards are the units where patients are hospitalized for a long period of time and medical equipment (catheter, sound, etc) is used. This equipment predisposes opportunistic infections if there isn't effective isolation (1). Multidrug resistant *P.aeruginosa* has frequently been reported as the cause of nosocomial outbreaks of infection in surgery wards (9). In our hospital, *Pseudomonas* isolations were higher in surgical wards than medical wards ($p < 0.05$). But there was no significant difference in *Pseudomonas* isolation rates between ICU and non ICU surgical wards where effective isolation couldn't be enforced. *Pseudomonas* isolation is generally carried out in IW-ICU on patients suffering from chronic and malignant diseases who are using immunosuppressed drugs and/or medical prosthetic devices. The rate of *Pseudomonas* infections in IW-ICU was higher than in IW-nonICU in our hospital ($p < 0.05$).

In this study, tracheal aspirate is an important source of *Pseudomonas* sp only in internal wards of ICU ($p < 0.05$) because *Pseudomonas* colonies in the

airway and infection are able to spread in IW-ICU (18). Specimens are generally taken in aseptic conditions in surgical wards, but epithelial and mucosal erosions lead to *Pseudomonas* colonisation. In a report from France, *P.aeruginosa* was the commonest bacteria of the respiratory tract in SW-ICU (17). In our report, isolation from tracheal aspirates in surgical wards ICU and sputum in SW-nonICU have a significant value (62.96%, $p < 0.001$; 16.66%, $p < 0.05$). Isolation from pus in SW and ICU, and non-ICU were important (4.2%, $p < 0.001$; 34%, $p < 0.05$). Also isolations from pus were important in SW and ICU (4.2%, $p < 0.001$; 34%, $p < 0.05$). The impairment of the skin, the presence of surgical instruments, for example catheter, the contaminated washing out solutions used by the staff and hospitalization for a long period of time are the predisposing factors for the *Pseudomonas* sp infections (19). 13-22.1% *P.aeruginosa* isolation rate was reported from pus (20,21).

Immunosuppressed patients are hospitalized for a long period and they generally use high doses of antibiotic. It is necessary to take the throat culture and detect resistance before admittance to hospital in order to detect carriers.

CRO and CTX are the commonest 3th generation antibiotics in ICU protocols. CAZ has a key role in resistance detection in ICU. But ICU antibiotic therapy protocols are different in almost all countries and there are regional differences (22). MIC₉₀ values were reported as 8 µg/ml and ≥ 38 µg/ml by Kessler et al and Verbist et al respectively (23,24). These rates corresponded to our study (32 µg/ml). Resistance to CAZ was reported as 4-18 in ICU (24-27). That is consistent with our result (13.3%). Resistance to CRO and CTX are significant in our study (8.4-15.0%). There was cross resistance between these two antibiotics because of the similarity of molecular structure (22). Previous studies suggest that the selective pressure from the use of antimicrobial agents is a major determinant for the emergence of resistant strains. The resistance to quinolone group antibiotics of *Pseudomonas* is variable in different centers. Resistance to CIP in ICU was reported as 8-31% (1, 26, 29, 30). Quinolone resistance in our study is the same as these reports (Table X). Nowadays, quinolones are the recommended antibiotics for respiratory tract infections. It is unusual to find resistance to quinolone in isolates from sputum (Table XI). This resistance should be discussed according to the source of the material and clinics because of prolonged and overused antibiotic usage. In report from Sweden, quinolone resistance was always crossed to resistance to either or both of the β -lactams and the aminoglycosides (22,30).

Minimizing and controlling antibiotic use in ICU patients should help reduce the risk of antimicrobial resistance in *Pseudomonas* bacteria. The extensive use of broad-spectrum antibiotics in the hospital can be probably responsible for the emergence and selection of resistant strain.

References

- Gilligan PH: *Pseudomonas* and *Burkholderia*. In *Manual of Clinical Microbiology* (Eds. Murray RR, Baron EJ, Tenover MA, Tenover FC, Tenover RH) American Society for Microbiology, Washington DC, 1995, pp 509-519
- Jarvis WR, Martone WJ: Predominant pathogens in hospital infections. *J Antimicrob Chemother.* 29 Suppl A:19-24, 1992
- Trilla A: Epidemiology of nosocomial infections in adult intensive care units. *Intensive Care Med.* 20 Suppl 3: S1-4, 1994
- Maniatis AN, Trougakos IP, Katsanis G, Palermos J, Maniatis NA, Legakis NJ: Changing patterns of bacterial nosocomial infections: a nine-year study in a general hospital. *Chemotherapy.* 43: 69-76, 1997
- Stein WE, Weinstein RA, Dixon RE: Comparison on endemic and epidemic nosocomial infections. *Am J Med.* 70(2): 393-7, 1981
- Ayliffe GAJ, Collins BJ, Taylor LJ: *Hospital acquired infection; principles and prevention*, London, 1990, p: 2
- Emori TG, Gaynes RP: An overview of nosocomial infectious including the role of the microbiology lab. *Clin Microbiol Rev.* 6(4): 428-442, 1993
- Morris AJ, Bremner DA, Jones MR, Schousboe MI: Susceptibility patterns of bacterial isolates from intensive care and haematology/oncology patients in New Zealand. *N Z Med J.* 23: 187-9, 1997
- Hsueh P, Teng LJ, Yang P et al.: Persistence of a multidrug-resistant *Pseudomonas aeruginosa* clone in an intensive care burn unit. *J Clin Microbiol.* 36(5): 1347-1351, 1998
- Suzuki Y, Koguchi M, Tanaka S et al.: Frequency of clinical isolation of glucose nonfermentative gram negative rods and their susceptibilities to antibacterial agents. *Jpn J Antibiot.* 48(9): 1264-1273, 1995
- Holmes B: The identification of *Pseudomonas cepacia* and its occurrence in clinical material. *J Appl Bacteriol.* 61: 299-314, 1986
- Noble RC, Overman SB: *Pseudomonas stutzeri* infection. A review of hospital isolates and a review of the literature. *Diag Microbiol Infect Dis.* 19(1): 51-56, 1994
- Planes AM, Ramirez A, Fernandez F, Capdevilla JA, Tolosa C: *Pseudomonas vesicularis* bacteraemia. *Infection.* 20(6): 367-8, 1992
- Calegari L, Gezuele E, Torres E, Carmona C: Botryomycosis caused by *Pseudomonas vesicularis*. *Int J Dermatol.* 35: 817-818, 1996
- Otto LA, Deboo BS, Capers EL, Picketts MJ: *Pseudomonas vesicularis* from cervical specimens. *J Clin Microbiol.* 7(4): 341-345, 1978
- Aragone MR, Maurizi DM, Clara LO, Navarro Estrada JL, Ascione A: *Pseudomonas mendocina*, an environmental bacterium isolated from a patient with human infective endocarditis. *J Clin Microbiol.* 30(6): 1583-1584, 1992
- Jarlier V, Fosse T, Philippon A: Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). *Intensive Care Med.* 22(10): 1057-1065, 1996
- Kerr JR, Moore JE, Curran MD et al.: Investigation of a nosocomial outbreak of *Pseudomonas aeruginosa* pneumonia in an intensive care unit by random amplification of polymorphic DNA assay. *J Hosp Infect.* 30: 125-131, 1995
- Goldmann DA, Pier GB: Pathogenesis of infections related to intravascular catheterization. *Clin Microb Rev.* 6(2): 176-192, 1993
- Twun-Danso K, Grant C, Il-Suleiman SA et al.: Microbiology of postoperative wound infection: a prospective study of 1770 wound. *J Hosp Infect.* 21: 29-27, 1992
- Dibb WL: Microbial aetiology of otitis externa. *J Infect.* 22(3): 233-239, 1991
- Nathwani D: Sequential switch therapy for lower respiratory tract infections: A European perspective. *Chest.* 113: 211S-218S, 1998
- Kessler RE, Fung-Tomc J: Susceptibility of bacterial isolates to beta-lactam antibiotics from US clinical trials over a 5-year period. *Am J Med.* 100(6A): 13S-19S, 1996
- Verbist L: Epidemiology and sensitivity of 8625 ICU and hematology/Oncology bacterial isolates in Europe. *Scand J Infect Dis.* 91: 14S-24S, 1993
- Puri J, Revathi G, Kundra P, Talwar V: Activity of third generation cephalosporins against *Pseudomonas aeruginosa* in high risk hospital units. *Indian J Med Sci.* 50(7): 239-243, 1996
- Snydman DR: Clinical implications of multi-drug resistance in the intensive care unit. *Scand J Infect Dis.* 78: 54S-63S, 1991
- Archibald L, Phillips L, Monnet D, McGowan JE Jr, Tenover F, Gaynes R: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care units. *Clin Infect Dis.* 24(2): 211-215, 1997
- Acar JF, Goldstein FW: Trends in bacterial resistance to fluoroquinolones. *Clin Infect Dis.* 24: 67S-73S, 1997
- Sofianou D, Tsakris A, Skoura L, Douboyas J: Extended high level cross resistance to antipseudomonal antibiotics amongst *Pseudomonas aeruginosa* isolates in a university hospital. *J Antimicrob Chemother.* 40: 740-742, 1997
- Tassios PT, Gennimata V, Maniatis A et al: Emergence of multidrug resistance in ubiquitous and dominant *Pseudomonas aeruginosa* serogroup O:11. *J Clin Microbiol.* 36(4): 897-901, 1998

Correspondence to:

Uzm. Dr. Çağrı ERGİN

Süleyman Demirel Üniversitesi

Tıp Fakültesi Hastanesi Kln. Mikrobiyoloji ve

Enfeksiyon Hastalıkları ABD

Isparta, TÜRKİYE